Complement Factor P

Introduction of Complement Factor P

Complement Factor P (CFP), also known as properdin, is the only known positively charged (pI>9.5) regulator of complement system. Factor P is a 53-kDa monomer composed of 6 globular domains that are homologous to the thrombospondin type 1 repeat (TSR), labeled TSR 1-6. Consisted of 442 amino acid residues, factor P is 26 nm in length and 2.5 nm in diameter, meanwhile, each subunit harbors a single N-glycosylation site in TSR-6 and is C-mannosylated at 14 different tryptophans, making properdin one of the most highly mannosylated proteins known. Significantly, native factor P subunits form head-to-tail dimers, trimers, and tetramers that resemble rods, triangles, and squares, respectively. And different formations usually present the fixed ratio 22:52:28.

Structure of factor P.

Fig.1 Structure of factor P. (Blatt, 2016)

Function of Complement Factor P

Factor P is historically recognized as a stabilizing component of the alternative pathway convertases, the central enzymes of the complement cascade. However, weighty evidence has revealed that factor P can also bind to target cells, phagocyte receptors, and serum regulators, providing a platform for convertase assembly and function, and promotes target phagocytosis.

  1. Direct Regulation of Alternative Pathway Activity

Factor P can enhance alternative pathway activity via two ways: (1) acting as a positive regulator of pre-existing alternative pathway activity or (2) initiating new alternative pathway activity. Acting as a positive regulator, factor P can stabilize the C3 convertase (C3bBb) of the alternative pathway, increasing their activity five to ten-fold. Factor P acts as a pattern recognition molecule to bind selectively to specific surfaces upon which it recruits C3b or C3(H2O) to direct and trigger alternative pathway.

  1. Binding to Apoptotic T Cells to Promote Phagocytosis

Factor P can bind early apoptotic T cells, which promotes their phagocytic uptake by macrophages and dendritic cells. Additionally, surface-bound factor P directed deposition of C3b activation fragments on apoptotic T cells to enhance complement activation.

  1. Binding to Microbial Pathogens

Factor P is showed directly to bind Neisseria gonorrhoeae and the resulting bacteria:properdin complexes induce C3 deposition to the microbial surface, which is beneficial for activation of complement pathway. These observations may account for why properdin-deficient individuals are particularly sensitive to meningococcal disease.

Regulation of factor P in alternative pathway.

Fig.2 Regulation of factor P in the alternative pathway. (Blatt, 2016)

Factor P and Disease

Factor P has been invariably found to be critical for alternative pathway activation, so a number of disorders mediated by the alternative pathway have close relevance with factor P. Indeed, apart from N. meningitides infection in P-deficient individuals, some autoimmune disease, most notably the development of systemic lupus erythematosus (SLE) and renal diseases are also associated with factor P. So factor P may represent a promising therapeutic target in clinical.

With rich research experiences in drug discovery and complement therapeutic field, Creative Biolabs' outstanding research team are providing high-quality biotherapeutics development services based on the complement system. We offer turn-key or ala carte services customized to our client’s needs. If you are interested in our platform, please contact us for detailed information.

Reference
1. Blatt, A. Z.; et al. Properdin: a tightly regulated critical inflammatory modulator. Immunological reviews. 2016, 274(1): 172-190.

Related Product

Questions & Answer

A: Complement factor P interacts with various complement components, including C3, C3b, and C3 convertase. It stabilizes the C3 convertase complex, prolonging its activity and amplifying the alternative pathway. Complement factor P can also bind to surfaces such as microbial pathogens, facilitating the opsonization and destruction of these invaders.

A: Yes, complement factor P-targeted therapies could have broader applications beyond autoimmune diseases. They might be explored for conditions involving excessive inflammation, tissue damage, or dysregulated immune responses, such as sepsis, transplant rejection, and certain neurological disorders.

A: Understanding the role of complement factor P in disease pathology can guide the development of targeted therapies. Insights into its interactions, structural features, and regulatory mechanisms can aid in designing drugs that modulate its activity, either by enhancing or inhibiting its function, leading to novel and more effective treatment strategies.

For Research Use Only.
Complement System

Online Inquiry